| 0 (0%) | 02-21 12:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 124.87 | 1-year : | 133.15 |
| Resists | First : | 106.91 | Second : | 114 |
| Pivot price | 102.76 |
|||
| Supports | First : | 95.44 | Second : | 79.4 |
| MAs | MA(5) : | 100.96  |
MA(20) : | 102.98 |
| MA(100) : | 105.07 |
MA(250) : | 85.64 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 37.7 |
D(3) : | 38 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 122.19 | Low : | 45.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RYTM ] has closed above bottom band by 29.4%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 103.67 - 104.19 | 104.19 - 104.62 |
| Low: | 96.05 - 96.58 | 96.58 - 97.02 |
| Close: | 98.99 - 99.84 | 99.84 - 100.53 |
Fri, 20 Feb 2026
Royal Bank Of Canada Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Moderate Buy - MarketBeat
Fri, 20 Feb 2026
Peak Rhythm Combines Rhythm & Climbing On Quest Next Month - UploadVR
Thu, 19 Feb 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Hunter Smith Sells 4,385 Shares - MarketBeat
Thu, 19 Feb 2026
Expert Outlook: Rhythm Pharmaceuticals Through The Eyes Of 11 Analysts - Benzinga
Thu, 19 Feb 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
Thu, 19 Feb 2026
RBC Capital Initiates Coverage on RYTM with 'Outperform' Rating - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 67 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 111.7 (%) |
| Shares Short | 6,290 (K) |
| Shares Short P.Month | 5,580 (K) |
| EPS | -3.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.23 |
| Profit Margin | -110.4 % |
| Operating Margin | -102.7 % |
| Return on Assets (ttm) | -26.8 % |
| Return on Equity (ttm) | -85.8 % |
| Qtrly Rev. Growth | 54.2 % |
| Gross Profit (p.s.) | 2.33 |
| Sales Per Share | 2.61 |
| EBITDA (p.s.) | -2.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -109 (M) |
| Levered Free Cash Flow | -147 (M) |
| PE Ratio | -32.19 |
| PEG Ratio | 0 |
| Price to Book value | 44.74 |
| Price to Sales | 38.19 |
| Price to Cash Flow | -61.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|